Literature DB >> 30349607

The Use of Sorafenib in the Thyroid Cancer.

Aneta L Zygulska1, Krzysztof Krzemieniecki2, Anna Sowa-Staszczak2.   

Abstract

There are not effective therapies for metastatic unresectable, non-RAI-avid thyroid carcinomas. Fortunately, thyroid carcinomas represent a promising paradigm for targeted therapy due to the presence of activing mutations of genes coding the kinase tyrosines which are involved in all functions of cancer cells (such as: growth or invasion). In this paper an efficacy and toxicity of sorafenib, one of the multi-kinase inhibitors in thyroid carcinomas treatment is presented.

Entities:  

Keywords:  multi-kinase inhibitor; sorafenib; thyroid carcinoma

Year:  2013        PMID： 30349607      PMCID： PMC6193511          DOI： 10.17925/EE.2013.09.01.28

Source DB:  PubMed          Journal:  Eur Endocrinol        ISSN： 1758-3772


  42 in total

Review 1.  Vascular endothelial growth factor in thyroid cancers.

Authors:  Jen-Der Lin; Tzu-Chieh Chao
Journal:  Cancer Biother Radiopharm       Date:  2005-12       Impact factor: 3.099

2.  Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

Authors:  David S Hong; Maria E Cabanillas; Jennifer Wheler; Aung Naing; Apostolia M Tsimberidou; Lei Ye; Naifa L Busaidy; Steven G Waguespack; Mike Hernandez; Adel K El Naggar; Alder K El Naggar; Savita Bidyasar; John Wright; Steven I Sherman; Razelle Kurzrock
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

Review 3.  Targeted therapy of thyroid cancer.

Authors:  Steven I Sherman
Journal:  Biochem Pharmacol       Date:  2010-05-13       Impact factor: 5.858

4.  Treatment with sorafenib in advanced thyroid cancer - a case report.

Authors:  Jolanta Krajewska; Tomasz Olczyk; Józef Roskosz; Ewa Paliczk-Cieślik; Aleksandra Kukulska Anetta Smietana; Bożenna Kaczmarek-Borowska; Barbara Jarząb
Journal:  Endokrynol Pol       Date:  2010 Sep-Oct       Impact factor: 1.582

5.  Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.

Authors:  Francesco Perri; Giuseppe Di Lorenzo; Giuseppina Della Vittoria Scarpati; Carlo Buonerba
Journal:  World J Clin Oncol       Date:  2011-03-10

Review 6.  Management of medullary thyroid cancer.

Authors:  D W Ball
Journal:  Minerva Endocrinol       Date:  2011-03       Impact factor: 2.184

7.  Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

Authors:  Panayiotis Savvides; Govardhanan Nagaiah; Pierre Lavertu; Pingfu Fu; John J Wright; Robert Chapman; Jay Wasman; Afshin Dowlati; Scot C Remick
Journal:  Thyroid       Date:  2013-04-18       Impact factor: 6.568

Review 8.  Medullary thyroid cancer: molecular biology and novel molecular therapies.

Authors:  Mehtap Cakir; Ashley B Grossman
Journal:  Neuroendocrinology       Date:  2009-05-25       Impact factor: 4.914

9.  Phase II trial of sorafenib in metastatic thyroid cancer.

Authors:  Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

10.  New targeted therapies for thyroid cancer.

Authors:  Alessandro Antonelli; Poupak Fallahi; Silvia M Ferrari; Ilaria Ruffilli; Francesca Santini; Michele Minuto; David Galleri; Paolo Miccoli
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.